Overview of antidepressants on the pharmaceutical market of Ukraine and dynamics of their consumption during 2015-2019

Abstract

Among persistent health and disability disorders in Ukraine, the third place among men and the second among women are neuropsychiatric disorders, in the pharmacotherapy of which antidepressants are widely used.
 The aim of the work was to study the range and outpatient and hospital consumption of antidepressants in Ukraine.
 The analysis of the range and volume of antidepressant consumption was conducted in the outpatient market during 2015–2019 and in the hospital market during 2016–2019, according to the analytical company «Proxima Research»/«Morion». Consumption was calculated according to the ATC/DDD methodology. DDD/1 000 inhabitants per day (DID, DDD per 1 000 inhabitants per day) was used as a unit of measurement.
 The results of the study showed that in the pharmaceutical market of Ukraine during 2015–2019, 94–101 tons of antidepressants were used on an outpatient basis, including 29–36 tons of domestic production and 65 tons of foreign manufacturers. In 2016–2019, the hospital used a smaller number of antidepressants TH – 78–79 TH, including 27–29 TH of domestic production and 52–49 TH – imported. The number of trade names of antidepressants in outpatient consumption is 16–22% higher than the number of trade names in hospital consumption, which may be due to lower government procurement of drugs in this group. It was found that outpatient consumption of antidepressants in the period 2015–2019 increased 2.22 times – from 1.08 DID in 2015 to 2.40 DID in 2019. Consumption in hospitals was much lower and ranged from 0.20 DID in 2016. Up to 0.19 DID in 2019 (With a peak of 0.24 DID in 2017). The increase in the use of outpatient antidepressants was gradual, without abrupt changes. Most INN antidepressants, with the exception of N06AX20 Various drugs and the herb St. John's wort N06AX25, have been included in modern medical and technological documents: the State State form of drugs (8–11 issues) and the List of domestic and foreign drugs that can be purchased by health facilities, which are fully or partially funded from the state and local budgets (2015–2017), which indicates their proven clinical efficacy and safety.